Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 4/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22910558 | 1.00 | ENPP2 (0.43) | ENPP2ATXN2CFDHRH4HRH3 | |
| SCHEMBL22911045 | 0.90 | ALDH1A1 (0.40) | FASNALDH1A1 | |
| SCHEMBL18082351 | 0.90 | ALDH1A1 (0.40) | FASNALDH1A1 | |
| SCHEMBL22910559 | 0.90 | ENPP2 (0.41) | ENPP2ATXN2CFDHRH4HRH3 | |
| SCHEMBL16759850 | 0.88 | ABCB1 (0.37) | ENPP2ATXN2CFDHRH4HRH3 | |
| SCHEMBL22911069 | 0.85 | ENPP2 (0.59) | ENPP2ATXN2HRH4HRH3MEN1 | |
| SCHEMBL16759931 | 0.85 | ENPP2 (0.59) | ENPP2ATXN2HRH4HRH3MEN1 | |
| SCHEMBL16759852 | 0.85 | AKR1C3 (0.52) | ENPP2ATXN2HRH4HRH3POLB | |
| SCHEMBL22910988 | 0.85 | AKR1C3 (0.52) | ENPP2ATXN2HRH4HRH3POLB | |
| SCHEMBL16759867 | 0.80 | AKR1C3 (0.44) | ENPP2ATXN2HRH4HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20160264586-A1 | OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264586-A1 | OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264586-A1 | OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | ENPP2 2448/4885ATXN2 1316/4885CFD 2539/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | ENPP2 2566/4885ATXN2 1217/4885CFD 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.